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This article has two main purposes. Firstly, to model the integrated healthcare expenditure for the 
entire population of a health district in Spain, according to multimorbidity, using Clinical Risk Groups 
(CRG). Secondly, to show how the predictive model is applied to the allocation of health budgets.  
Methods 
The database used contains the information of 156,811 inhabitants in a Valencian Community health 
district in 2013. The variables were: age, sex, CRG’s main health statuses, severity level, and 
healthcare expenditure. The two-part models were used or predicting healthcare expenditure. From the 
coefficients of the selected model, the relative weights of each group were calculated to set a case-mix 
in each health district. 
 
Results 
Models based on multimorbidity-related variables better explained integrated healthcare expenditure. 
In the first part of the two-part models, a logit model was used, while the positive costs were modelled 
with a log-linear OLS regression. An adjusted R2 of 46-49% between actual and predicted values was 
obtained. With the weights obtained by CRG, the differences found with the case-mix of each health 
district proved most useful for budgetary purposes. 
 
Conclusions 
The expenditure models allowed improved budget allocations between health districts by taking into 
account morbidity, as opposed to budgeting based solely on population size.  
 
Keywords: Budget; Case-mix system; Health econometrics; Healthcare expenditure; Multimorbidity; 






The demographic change that the more developed countries, such as Spain, are undergoing and which 
is characterised by increased life expectancy and population ageing, is a major challenge that threatens 
the sustainability of both state health care systems and the welfare state. The main consequence of this 
new population configuration is the higher prevalence of chronic diseases, given the phenomenon of 
multimorbidity [1–3]. Together with the negative outcomes associated with multimorbidity, such as 
mortality, disability and deficient quality of life, we also see an increase in associated costs. 
Predicting healthcare expenditure according to morbidity gives rise to two methodological questions: 
how to measure multimorbidity and which predictive models to choose. Regarding the former, a valid 
alternative is to use a risk adjustment system. Risk adjustment systems were developed to determine 
the multimorbidity profile and the population’s general health status in order to establish capitation 
payment in medical service provision and better planning for health services. These systems are based 
on the diagnostics registered in electronic health databases and each individual is classified into a 
multimorbidity group. The most widely used patient classification systems for risk adjustments in 
health based on diagnostics are: Adjusted Clinical Groups (ACG) [4], Diagnostic Cost Groups (DCG) 
[5,6] and Clinical Risk Groups (CRG) [7]. 
CRGs have been applied to budgetary planning [8], to the comparison of health service utilization and 
expenditure between different risk groups [9,10] and to the identification of high cost complex patients 
[11–14]. 
In this work, we use CRG as measure of multimorbidity. The CRG system classifies patients into 
different morbidity groups through disease codes from an electronic health record, using individual 
information on acute episodes and treatments for chronic conditions. From this information, each 
person is assigned to one of the 1,076 (depending on the version) CRGs. Each group is mutually 
exclusive and each individual is classified into categories with common clinical characteristics and 
similar consumption patterns. Moreover, each group can, in turn, be grouped into different aggregates 
as one of nine CRGs or mean health statuses (MHS). These nine MHS contain at least six levels that 
identify each group’s severity, though some CRG groups consider only five, four or two. The 
aggregation level that considers the nine MHS and the six severity levels is called an Aggregated 
Clinical Risk Group 3 (ACRG3) [7]. 
The second concern addresses how to model healthcare expenditures, as these dependent variables 




Ordinary least squares (OLS) lineal regression based on normal distribution has traditionally been used 
[4,16–18]. To correct the right-skewness of healthcare expenditure, early approaches considered a 
transformation of the data, such as a logarithmic transformation through an OLS regression model. 
However, there is a risk of the error term of model. To solve this, it is possible to go from the E(ln(y/x) 
to the ln(E(y/x) by retransformation [19,20]. Other authors have begun to use generalized linear models 
(GLM) [21–27]. GLM methodology offers advantages over OLS regression: 1) the data dealt need not 
follow a normal distribution, nor meet homoscedasticity criteria; 2) it provides estimates of the 
ln(E(y/x) and E(y/x) directly, without any requirement for retransformation [28]. GLM are 
characterised by the possibility of adopting different types of probability distributions (Gamma, 
Poisson, Binominal, etc.). 
Another problem in analysing healthcare expenditure is a possible large mass of observations with 
zero-cost [29]. Different studies have adopted different solutions for this: 1) adding a positive constant 
k to the costs, thus modelling the log(cost+k), usually in an OLS framework [8]. This has the previously 
mentioned problem of back-transformation [19], which can be avoided by using GLM and not taking 
into account different behaviours of patients with zero-costs. 2) using the Tobit model based on the 
concept of latent variable. 3) using a mixed model that explicitly takes into account the different nature 
of the populations, one with positive and the other with zero-cost [30]. The expectation is split in two 
parts, the first modelling the probability of any expenditure, based on the full sample. The second 
models the actual level of expenditure conditionally to c>0. Here, the following distinctions are made 
[31]: 1) if the distribution allows for zeros, then those models with a separate zero cost mechanism are 
called zero-inflated models; 2) if the distribution does not allow for zeros, those models with a separate 
zero cost mechanism are commonly called two-part models. The two-part model is based on a 
statistical decomposition of the density of the outcome into a process that generates zeros and a process 
that generates positive values [15].  
It must be kept in mind that the two-part models can also have the problem of retransformation if the 
second part of the model is based on a transformation, e.g. a logarithmic transformation. To avoid this, 
the substitution of the OLS model part for a Gamma model is a valid option [29].  
In Spain, CRG is used by various autonomous regions and organisations: the Basque country, the 
Valencian Community (VC) [32,33] and the Baix Empordà (Girona) [11,34–37]. In these cases, the 
regression models used are adjusted by OLS either in their original form or through the logarithmic 




expenditure other than zero has been modelled using GLM [38], as has the pharmaceutical prescription 
expenditure using a variant of CRG called adjusted morbidity groups (AMG) [39].  
Thus, the two main purposes of this article are: 1) to model the expenditure of integrated health care 
(hospital, primary health care (PHC) and pharmaceutical prescription) for the entire population of a 
health district of the VC according to multimorbidity, using CRG. 2) to show how the predictive model 
is applied to the allocation of health budgets.  
Previous works carried out in the VC [32,40] have modelled the pharmaceutical expenditure for the 
whole population. However, the present work models the total health expenditure and, moreover, the 
expenditure for the whole population (0 cost included), which represents a new contribution compared 
with a previous work carried out in Girona [34].  
The availability of a system that relates multimorbidity and expenditure is a highly relevant innovation 
for some health systems. As well as establishing predictive budgets at different levels of the system 
for the health district, health centre and practitioner, it can be used to assign other resources, such as 
human resources.  
 
2. Materials and Methods 
2.1. Design and study area 
This is a cross-sectional study of total healthcare expenditure and its application in clinical 
management using predictive models. A database of the 156,811 inhabitants was available that make 
up the Denia Health District (DHD) of the VC that is managed according public–private partnership 
agreement [12]. For each individual, the database contains age, sex, MHS, severity level, 
pharmaceutical expenditure (in euros), PHC expenditure (in euros) and hospital expenditure (in euros). 
All data was taken from 2013.  
2.2. Sources of information 
From the Regional Ministry of Health (Conselleria de Sanitat), the information sources on the patients 
are: the Population Information System (SIP), which holds the identifying and demographic variables 
of the patient; the Ambulatory Information System (SIA-GAIA), which gathers the pharmacy 




patient into a CRG (standard version 1.6). This information is available for all the health districts, 
including DHD.  
Information on hospital expenditure for the DHD was provided by the Denia Hospital Management 
Control services, and includes costs for hospitalisation, surgery, outpatient consultations, laboratory, 
medical imaging, outpatient oncology care, dialysis and referrals to other hospitals. PHC expenditure 
was not obtained directly from the accountancy services of the Regional Ministry of Health, but was 
calculated from the official prices according to the Public Tariffs Law (Ley de Tasas) of the VC [41] 
and the number of contacts made with the health service. 
2.3. Modelling 
We used two-part models to estimate four dependent variables: total healthcare expenditure, 
pharmaceutical prescription expenditure, PHC expenditure and hospital expenditure. Only the 
predictions for total healthcare expenditure were used to construct a capitation model and assign 
budgets to VC health districts.  
With two-part models there are four main modelling choices [15]. The first is to select the first part of 
two-part model. The first part is usually modelled via a probit: 
 
𝑃𝑟(𝑐𝑖 > 0 𝑥𝑖⁄ ) = 𝜙(𝑥
,𝛽)                        [1] 
Where 𝜙 represents the standard normal cumulative distribution function, or via a logit: 
 




,𝛽                                   [2]  
 
We chose a logit model to define the probability of costs greater than 0. The second and third choices 
correspond to the modelling of positive costs, using the  Manning and Mullahy algorithm [28,38,42].  
Distributions considered for the positive costs are an appropriate model in the log-linear OLS or the 
GLM class with a log link: 
Log-linear OLS: Log ci  = α+βXi +εi                 [3] 
GLM with a log link: ci = eα+βXi+εi                     [4] 
The final result of the two-part model is obtained by [29]: 
𝐸(𝑐𝑖 𝑥𝑖⁄ ) = 𝑃𝑟(𝑐𝑖 > 0 𝑥𝑖⁄ )𝐸(𝑐𝑖 𝑥𝑖⁄ , 𝑐𝑖 > 0)                               [5] 




We further designed five models with different explanatory variables. Model 1: age and sex; Model 2: 
MHS and severity; Model 3: MHS, severity, age and sex; Model 4: ACRG3; Model 5: ACRG3, age 
and sex. The variables sex, ACRG3, MHS and severity were dummy variables. The variable sex took 
the value 1 if it was male and 0 otherwise. 
We estimated the two-part model and statistical test in Stata, using the twopm command [43,44]. 
 
2.4. Specification tests, goodness of fit and validating the model 
We tested the specification of the explanatory variables in the second part by conducting Pregibon’s 
link test [45], a modified Hosmer-Lemeshow test [46], the Root Mean Square Error (RMSE), the Mean 
Absolute Percentage Error (MAPE), the Median Absolute Percentage Error (MEDAPE) and the 
adjusted coefficient of determination (𝑅2) between the logarithm of the current values and those 
predicted by the models.  
Using the model for total healthcare expenditure, an estimated total expenditure for each value of the 
explanatory variables was obtained. To corroborate that the selected model was also the one with the 
strongest predictive power for the total actual expenditure, the mean predictive of total actual cost by 
decile will be calculated. Also we will plot the predicted means across the range of predicted values 
for the predictive total expenditure per decile. This enables visual detection of the MHS that have 
greater variability than the mean [42].  
 
 
2.5. Obtaining weights and case-mix system 
The weights of each multimorbility group were obtained from the quotient between the healthcare 
expenditure of each multimorbility group and the healthcare expenditure of the healthy group. These 
weights were used to obtain the adjusted patients for each district in the VC (number of individuals of 
each ACRG3 * weight of ACRG3) and their case-mix (adjusted patients/total population) for adjusted 
capitation budgeting purposes.  
This research was approved by the Behavioural Research Ethics Board at the Generalitat Valenciana 
on January 30, 2014, with protocol code RUTFAR- 2013-01, version of 19 December 2013. The 





3.1. Descriptive analysis 
Table 1 shows the number of individuals, average age, female population and total healthcare 
expenditure (€/inhabitant) for each MHS and severity level. The patients with the highest average 
expenditure were those in MHS 9, with an average of €14,423. 
Generally, the total average healthcare expenditure increases with the number and intensity of chronic 
diseases. The high standard deviation and a median value that was notably lower than the average in 
each MHS indicates wide variability in expenditure and a high concentration in a small part of the 
population. The average age also increases systematically with the number of chronic diseases, going 
from 33.8 years old for the healthy status to reach 75.9 in MHS 7. However, in MHS 8 and 9, which 
refer to malignant diseases and catastrophic conditions with a strong economic impact (cystic fibrosis, 
transplants, etc.), the average age descends, as these conditions are less tied to an age group than the 
other chronic conditions in MHS 6 and 7. MHS 9 with severity level 6 is the MHS with the highest 
average expenditure (€42,881). ACRG3 10, the healthy group, represents 54.7% of the total 
population.  
3.2. Econometric modelling of healthcare expenditure according to morbidity 
The first modelling of the probability of any expenditure does not require a decision on the model to 
be chosen. Table 4, therefore, includes only results from the model selected. Table 2 shows the test 
results by model selection for second part between the five models designed with different explanatory 
variables. In all cases the kurtosis of residual analysis (log scale) of the GLM log-link estimator were 
higher than 3. This means that, according to the algorithm used, we must conduct log-OLS estimation 
instead of GLM. According to results of the modified Hosmer-Lemeshow, Pregibon’s link and 
MEDAPE, model 4 achieved the highest level of specification. This model, which included the 38 
multimorbidity groups of ACRG3 aggregation level as independent variable, had an adjusted 𝑅2  of 
46.4%, which was not the highest, but sufficient. Therefore, we used this model for analysing the other 
cost dependent variables and designing the predictive case-mix system for the health district’s budget 
assignation. 
The test results of the model’s estimation for pharmaceutical prescription, PHC and hospital 
expenditures are shown in Table 3. The pharmaceutical predictive model achieved the best results with 




In Table 4 (columns 2 and 3) we show the results from the two-part models for total healthcare 
expenditure, using multimorbidity groups classified by ACRG3. To obtain the predicted expenditure 
value for each group we retransformed the coefficients and also considered Duan’s smearing estimator 
(1,757) (column 4). Column 5 of Table 4 shows the total healthcare expenditure estimated from 
multiplying non-zero probability obtained from column 2 by the value of column 4. 
Figure 1 illustrates the predicted means across the range of predicted values for the predictive total 
expenditure per decile. The actual decil means form a 45º line. However, all groups of MSH 9 and 
group of MSH 7 which indicates they are under-predicted, while others (ACRG3 74, ACRG3 76 and 
ACRG3 84) fall below the line, which indicates they are over-predicted.  
 
3.3. Development of a case-mix model 
The process for the calculation of the weights to establish the case-mix system by multimorbidity 
groups is given in the in the last column of Table 4. From the value of column 5, the relative weight is 
calculated in column 6. 
Once the relative weights for each ACRG3 have been calculated, they are multiplied by the number of 
existing patients in each group of each VC health district to obtain the number of patients adjusted by 
morbidity. Dividing the value obtained in each health district by the number of total patients for that 
health district provides the case-mix. The results of these calculations are shown in figure 2. The 
districts with higher morbidity will require higher capitation financing. The case-mix oscillates 




The direct predecessor of this study was a modelling of pharmaceutical prescription expenditure from 
CRG stratification, which was also carried out in the VC [32,47]. However, the main contribution of 
the present work is to analyse not only prescription pharmaceutical expenditure, but also expenditure 
in PHC and hospital settings, both together and separately, for the entire population of 156,811 in the 




In this work we use a two-part model [15] as opposed to the log (cost+k) in an OLS with which 
previous works were carried out [32,47], and in other works [16,48,49]. In the second part of the model, 
log-linear OLS were always chosen, both for the different models of total expenditure and the different 
categories of expenditure, as opposed to other works where GLM has sometimes been chosen [38,42]. 
The adjusted R2 of 46.4-49.4% were similar to that obtained in other previous studies that used 
different patient classification systems. For example, a study carried out in Canada [16] used OLS 
regression and measured the explanatory and predictive quality of ACGs for total healthcare 
expenditure, which was 40%. Likewise, another study in Taiwan [48], relating total healthcare 
expenditure and ACGs through OLS regression, obtained an R2 of 41.1%. 
An R2 of 48.3% in pharmaceutical expenditure has been obtained by OLS regression, using a sample 
of 81,873 individuals in Spain [49], which is a similar figure to that of the present work. Nevertheless, 
it is important to note that the above - mentioned study only encompassed those patients in contact 
with the healthcare system, either out - or inpatients, which means that their research did not reflect 
those subjects who did not use the healthcare system. Conversely, our work covered the whole 
population in the DHD, including those inhabitants with a zero cost, providing another important 
contribution.  
Hospital expenditure had the lowest adjusted R2 (33.01%) of the three main expenditure categories, 
due to treatment of acute conditions requiring surgery, hospitalisation and cancer treatment, among 
others. This wide variability in the same MHS is because not all chronic patients classified in one 
group require hospitalisation. Thus, for example, a patient from MHS 6 may present a series of 
complications, while another from the same MHS might not. This means hospital expenditure is more 
heterogeneous in any given MHS with the same severity level, as even the same disease may require 
a different number of hospitalisation days, several types and numbers of surgical interventions, etc. 
Those patients also classified within the MHS may register hospital expenditure for a musculoskeletal 
system or some other condition. We must also take into account that pregnant women, classified in the 
healthy status, also use hospital resources during their pregnancy and delivery. On the other hand, 
pharmaceutical prescription expenditure had the best adjusted R2 (55.62%). 
The analysis of expenditure by deciles shows a greater deviation for patients from MHS 9 and high 
severity levels. This may be due to these groups having a very low population  and a high standard 
deviation. It may be the case that these groups are not fully represented in the models and new 




There are great differences in the case-mix between the health districts, ranging from 3.8 to 4.8. 
Therefore, in terms of establishing a case-mix system for budget allocation, the model explained in 
this study might be a useful approach in future applications, as previously shown for pharmaceutical 
prescription expenditure adjusted by morbidity with CRG [8]. 
While the model presented by Monterde et al [39] explained the pharmaceutical expenditure of the 
AMG using statistical GLM models adjusted to Poisson distribution, we concur with Inoriza et al. [36] 
on the methodological limitations of this proposal and the need to establish technical comparisons with 
models using CRG. 
Limitations 
The main limitation of this study was the population size considered, as it would have been desirable 
to have information on the total expenditure for the patients in various Health Districts. This, however, 
was not possible. Moreover, the PHC expenditure used in this study was obtained by applying an 
official standard tariff to the number of contacts made with this healthcare service, a figure obtained 
from estimations as this accounting information was also lacking. The case-mix model for the VC was 
established by extrapolating the weights obtained in the model for the DHD to the entire VC 
population. It would be recommendable for future research to be able to count on the whole population 
of the field of study. 
Regarding the modelling, we chose model 4 according to results of the modified Hosmer-Lemeshow, 
Pregibon’s link and MEDAPE. However, model 4 had the greatest RMSE. This RMSE would possibly 
be reduced by increasing the size of the sample by adding more health districts. 
Another limitation, also regarding the information available, concerns home and long term residential 
care. This information was unavailable and therefore could not be included. This needs to be included 
in future studies to obtain the total healthcare expenditure. Other studies with a similar setting to ours 
[38] also lack this information. 
Regarding external validity and extrapolation of the results, two requirements must be met. Firstly, 
that the multimorbidity classification system used is CRG, and secondly, that the cost structure is 
similar. However, the methodology and system offered in this work can be replicated with another 




In any case, considerable variability exists in the typology of research and tools used for clinical risk 
adjustment. Thus, it would be worthwhile for more healthcare administration institutions to conduct 
studies in this field in order to be able to compare results and obtain feedback [36]. 
 
5. Conclusions 
Multimorbidity grouping obtained from CRG patient classification system is a valid measure to predict 
healthcare expenditure. Good predictive power was achieved for pharmaceutical expenditure and total 
healthcare expenditure. Two-part models provided better estimations than other econometric models 
used for modelling healthcare expenditures. 
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Table 1. Average total healthcare expenditure and population distribution by mean health 






Severity level   




(54.7%)             
85,668 
 (54.7%) 
Mean age 33.8             33.8 
Female Population (%) 47.9%             47.9% 
Health Cost (€/inhab) 
Mean (SD) 
240.0  
(750)             
240.01  
(750) 





(3.9%)             
6,142 
 (3.9%) 
Mean age 36.9             36.9 
Female Population (%) 57.7%             57.7% 
Health Cost (€/inhab) 
Mean (SD) 
1,013.1  
(2,936)             
1013.1 
(2,936) 
3 Single Minor 
Chronic Disease 
Level 




(0.5%)         
15,610  
(9.9%) 
Mean age   47.5 42.9         47.3 
Female Population (%)   56.2% 65.7%         56.7% 
Health Cost (€/inhab) 




(4,636)         
680.1 
 (2,039) 









988 (0.6%) 106 (0.1%) 
    
6,607  
(4.2%) 
Mean age   56.6 62.1 58.6 59.7     58.1 
Female Population (%)   63.7% 70.2% 76.9% 78.3%     67.4% 
Health Cost (€/inhab) 



























Mean age   54.6 57.3 61.1 72.6 68.5 60.2 55.8 
Female Population (%)   52.1% 52.9% 42.3% 41.5% 49.2% 33.3% 51.5% 
Health Cost (€/inhab) 

































Mean age   67.6 70.2 71.8 74.0 75.8 73.1 69.5 
Female Population (%)   57.4% 50.3% 50.2% 50.4% 47.9% 54.1% 54.0% 
Health Cost (€/inhab) 

















In Three or More 
Organ Systems 















Mean age   74.4 75.5 76.6 78.8 76.2 68.6 75.9 
Female Population (%)   45.2% 40.6% 42.8% 46.9% 20.5% 30.0% 42.4% 
Health Cost (€/inhab) 
































Mean age   58.1 63.7 65.6 66.9 63.3  63.8 
Female Population (%)   49.5% 52.6% 31.9% 42.0% 69.6%  44.6% 
Health Cost (€/inhab) 






























Mean age   44.6 48.3 60.2 57.5 61.0 64.0 49.6 
Female Population (%)   44.1% 29.9% 43.7% 30.5% 28.6% 44.4% 34.6% 
Health Cost (€/inhab) 















TOTAL Population (%)              
156,811 
(100.0%) 




Female Population (%)               51.1% 
Health Cost (€/inhab) 








Table 2.  Manning-Mullahy algorithm results: Model choice for second part modelling of the 












RMSE MAPE MEDAPE 
Model 1 
Age and sex 





















0.494 1.05 0.15 0.11 
Model 4 
ACRG3 
















Table 3. Manning-Mullahy algorithm results: Model choice for second part modelling for each 














RMSE MAPE MEDAPE 
Pharmacy 103,273 3.27 Log-OLS 0 (1.000) 0,000 
(1.000) 
0.556 1.35 0.45 0.19 
PHC 124,703 4.20 Log-OLS 0 (1.000) 0,000 
(1.000) 
0.386 0.99 0.14 0.11 
Hospital 88,684 4.27 Log-OLS 0 (1.000) 0,000 
(1.000) 








Table 4.  Estimation of the relative weights of the ACRG3 from the results of the two-part model. 
 (1) 














(5) = P(c>0)*(4) (Euro) 
Relative weight 
(6) = (5)/185.6 
Constant 0.78 7.778    
ACRG3 1 0.00 -2.741 270.6             185.6    1.00 
ACRG3 2 5.84 -1.578 865.1             862.6    4.65 
ACRG3 31 2.47 -1.851 658.5             607.0    3.27 
ACRG3 32 Omitted * -0.810 1,858.3 1,858.3 10.01 
ACRG3 41 4.04 -1.376 1,059.5          1,041.2    5.61 
ACRG3 42 5.48 -0.985 1,565.5          1,559.0    8.40 
ACRG3 43 Omitted * -0.721 2,039.0          2,039.0    10.99 
ACRG3 44 Omitted * -0.360 2,924.7          2,924.7    15.76 
ACRG3 51 3.34 -1.191 1,274.4          1,230.8    6.63 
ACRG3 52 4.42 -0.703 2,076.8          2,052.2    11.06 
ACRG3 53 4.66 -0.387 2,847.1          2,820.4    15.20 
ACRG3 54 4.49 -0.299 3,108.6          3,074.2    16.57 
ACRG3 55 3.65 -0.142 3,639.6          3,547.6    19.12 
ACRG3 56 Omitted * 0.843 9,737.8          9,737.8    52.47 
ACRG3 61 5.11 -0.443 2,692.4          2,676.2    14.42 
ACRG3 62 5.71 -0.075 3,888.5          3,875.6    20.88 
ACRG3 63 5.87 0.121 4,734.3          4,721.0    25.44 
ACRG3 64 Omitted * 0.365 6,042.7          6,042.7    32.56 
ACRG3 65 Omitted * 0.547 7,243.5          7,243.5    39.03 
ACRG3 66 Omitted * 0.000 4,193.3          4,193.3    22.60 
ACRG3 71 Omitted * 0.131 4,779.5          4,779.5    25.76 
ACRG3 72 4.70 0.431 6,450.4          6,392.4    34.45 
ACRG3 73 Omitted * 0.636 7,919.5          7,919.5    42.68 
ACRG3 74 Omitted * 0.840 9,711.6          9,711.6    52.33 
ACRG3 75 Omitted * 1.127 12,944.2       12,944.2    69.75 
ACRG3 76 Omitted * 0.789 9,232.0          9,232.0    49.75 
ACRG3 81 3.27 0.012 4,243.3          4,088.4    22.03 
ACRG3 82 3.44 0.619 7,784.5          7,541.9    40.64 
ACRG3 83 4.73 0.842 9,733.4          9,648.5    51.99 
ACRG3 84 3.70 1.154 13,295.1       12,975.5    69.92 
ACRG3 85 Omitted * 1.253 14,674.4       14,674.4    79.08 
ACRG3 91 3.38 -0.080 3,869.0          3,741.9    20.16 
ACRG3 92 Omitted * 0.953 10,872.6       10,872.6    58.59 
ACRG3 93 Omitted * 2.061 32,943.0       32,943.0    177.52 
ACRG3 94 Omitted * 1.687 22,648.7       22,648.7    122.05 
ACRG3 95 Omitted * 2.260 40,190.5       40,190.5    216.58 
ACRG3 96 Omitted * 2.655 59,627.0       59,627.0    321.32 







Note Table 4: 
(*omitted) Groups with positive cost values only (P(c>0)=1)  
Column 2: Logit regression coefficients according to the equation [2]. 
Column 3: Log OLS regression coefficients according to the equation [3]. 








Each point refers to a multimorbidity group represented by two digits: the first digit is the 


















Figure 2. Case mix, population and adjusted patients for each health district in Valencian 
Community  
 
 
 
 
 
 
 
